Details of the Drug Reposition

General Information of This Drug (ID: DMHNFXR)

Drug Name	Chimeric Antigen Receptor Modified T cells Targeting CD19 DMHNFXR
Drug Type	CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
leukaemia	DISS7D1V	2A60-2B33	Phase 1/2	[1]
Lymphoma	DISN6V4S	2A80-2A86	Phase 1/2	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma